NEW YORK (GenomeWeb News) – Saladax Biomedical today announced the completion of a $9 million debt financing with GE Capital.
The secured loan facility will be used to support commercialization of Saladax's My5-FU assay, which measures levels of 5-flourouracil, a chemotherapy used in conjunction with other therapies for colorectal cancer and other solid tumors. The test is currently available in the European Union and Australia.